True, circulatory diseases would be a big win, but do you think the marginal buck there is likely to do as much as a marginal buck focused on aging giving the amount of funding allocated to each? If we add the R&D budgets focused on circulatory diseases to the treatment cost of circulatory diseases (potential profit pool for pharma companies), my intuition says that the number would be ~20-100x the total amount of funding to aging-stopping or -reversing technology. What do you think the ratio would be?
True, circulatory diseases would be a big win, but do you think the marginal buck there is likely to do as much as a marginal buck focused on aging giving the amount of funding allocated to each? If we add the R&D budgets focused on circulatory diseases to the treatment cost of circulatory diseases (potential profit pool for pharma companies), my intuition says that the number would be ~20-100x the total amount of funding to aging-stopping or -reversing technology. What do you think the ratio would be?